HIV-like virus suppressed in monkey experiment

Image
AP New York
Last Updated : Oct 31 2013 | 1:55 AM IST
Doctors may one day be able to control a patient's HIV infection in a new way: injecting swarms of germ-fighting antibodies, two new studies suggest.
In monkeys, that strategy sharply reduced blood levels of a cousin of HIV. The results also gave tantalising hints that someday the tactic might help destroy the AIDS virus in its hiding places in the body, something current drugs cannot do.
The study results "could revolutionise efforts to cure HIV" if the approach is found to work in people, said a commentary published today by the journal Nature along with the monkey studies.
Antibodies are proteins in the blood that grab onto specific germs and mark them for elimination. People infected with HIV naturally make antibodies to fight the AIDS virus, but they are generally ineffective. The two new studies used lab-made versions of rare antibodies with unusual potency against HIV.
One study of rhesus monkeys showed a profound effect from a single injection of antibodies, said lead author Dan Barouch of Harvard and the Beth Israel Deaconess Medical Center in Boston.
The 18 animals had been infected with SHIV, a monkey version of HIV. In 13 animals, blood levels of SHIV became undetectable by standard tests within a week of the treatment.
After the antibodies petered out, the virus came back. That happened one to three months after treatment.
In three monkeys with the lowest levels of SHIV before treatment, the virus didn't return during an observation period of up to eight months. Barouch said the animals were not cured, but the treatment had apparently improved their immune systems enough to keep the virus in check.
The two other monkeys started with the highest blood levels of SHIV. Treatment lowered those levels but not to the point where they were undetectable.
The second study in Nature, from the National Institutes of Health, showed encouraging results in a smaller group of monkeys.
In people, standard drugs routinely tamp down HIV to undetectable levels in the blood. But the antibody approach may someday help doctors attack virus that's hiding in infected cells, beyond the reach of today's drugs, said the Nature commentary by Steven Deeks of the University of California, San Francisco, and Louis Picker of the Oregon Health & Science University in Beaverton.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 31 2013 | 1:55 AM IST

Next Story